Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: September 2022
Date Filed: September 23, 2022
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K serves as a procedural report to incorporate an exhibit regarding a securities application rather than a financial results announcement.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this document. The primary event reported is the submission of an application for the quotation of securities (ATH).
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference into Registration Statements on Form S-8 and Form F-3.
Exhibit: Exhibit 99.1 contains the "Application for quotation of securities - ATH."
Risks and Contingencies: The filing text does not provide specific details on risks, contingencies, or unusual items beyond the standard disclosure of being a development stage enterprise.
Investor Verification Checklist
- Verify the status and approval of the "Application for quotation of securities - ATH" referenced in Exhibit 99.1.
- Review the incorporated Registration Statements (Form S-8 and Form F-3) for detailed capital structure and offering terms.
- Confirm the company's current cash position and runway, as this filing does not contain updated financial statements.
- Monitor for subsequent filings that may detail the outcome of the securities quotation application.